OncoHost Unveils New Study on Renal Cell Carcinoma Biomarkers

OncoHost, a pioneering technology firm in precision medicine, has commenced a significant research partnership with Dana-Farber Cancer Institute to identify biomarkers for renal cell carcinoma (RCC), a prevalent type of kidney cancer. This collaborative study aims to refine clinical decision-making and enhance patient outcomes by pinpointing specific biomarkers.

Immune-checkpoint inhibitor (ICI) therapy has revolutionized the treatment landscape for RCC, leading to significantly improved patient prognoses. However, this therapy is not universally effective and can cause immune-related adverse events (irAEs).

Dr. Ofer Sharon, CEO of OncoHost, expressed enthusiasm about the collaboration with Dana-Farber Cancer Institute, noting the critical need for reliable biomarkers in RCC. "As we advance in precision medicine, validated biomarkers are essential for guiding treatment strategies and understanding resistance mechanisms across various cancers. The absence of dependable biomarkers in RCC to predict ICI responses presents a challenge we aim to address, ultimately to enhance clinical decision-making and patient outcomes."

The collaboration will utilize Dana-Farber's extensive collection of patient plasma samples and related clinical data, critical components for OncoHost to develop a proteomic plasma profile. Dr. Wenxin Xu of Dana-Farber Cancer Institute and Harvard Medical School, who leads the study, highlighted the potential of this research. "Currently, RCC patients lack a blood test to guide personalized treatment. This study aims to determine if the analysis of numerous cancer-related proteins in blood samples can produce personalized, data-driven treatment predictions. Success in this area could deepen our understanding of RCC biology and its treatment responses."

The study's primary goals include developing a proteomic plasma profile for metastatic RCC patients before treatment, correlating protein expression changes with treatment response measures such as Best Response, Overall Survival, and Progression-Free Survival. Additionally, it will assess differential response predictions to specific treatment combinations.

Beyond these objectives, the research will investigate proteomic pathways associated with treatment response and irAEs, providing insights that could inform treatment strategies and reveal biological resistance patterns. Comparing these pathways to those identified in other cancers, as part of the PROPHETIC trial (NCT04056247), will further elucidate RCC's distinctive biomolecular characteristics.

OncoHost, headquartered in Binyamina, Israel, and Cary, North Carolina, is dedicated to advancing precision medicine to improve patient outcomes. Their proprietary platform, PROphet®, is a plasma-based proteomic analysis tool initially applied to non-small cell lung cancer (NSCLC), utilizing a single blood sample to guide first-line immunotherapy choices. The PROphetNSCLC™ test has demonstrated clinical utility by providing physicians with essential guidance on optimal first-line immunotherapy treatments, significantly impacting overall survival rates.

With an experienced team, robust clinical trials, and extensive patient recruitment, OncoHost is poised to lead the next phase of precision diagnostics and biomarker development, promising a transformative impact on cancer treatment and patient care.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!